Table 3.
Country | Author and year | Screened (n) | CDHL identified (n) | % of CDHL | NHL identified (n) | % of SNHL | Overall HL identified (n) | % of HL | 95% CI (LB to UP) |
India | Chadha et al.67 2013 | 15 718 | NA | NA | NA | NA | 1578 | 10.30 | 9.57 to 10.52 |
Shekhar et al.68 2020 | 474 | 146 | 30.80 | 1 | 0.21 | 147 | 31.01 | 26.87 to 35.39 | |
Turkey | Tokgöz-Yılmaz et al.72 2013 | 239 | 25 | 10.46 | 1 | 0.42 | 26 | 10.88 | 7.23 to 15.53 |
Kaplama et al.79 2020 | 23 664 | 186 | 0.79 | 89 | 0.37 | 275 | 1.16 | 1.03 to 1.31 | |
Iran | TarvijEslami et al.78 2017 | 2284 | 28 | 1.23 | 8 | 0.35 | 36 | 1.58 | 1.11 to 2.18 |
Jalali et al.73 2020 | 2019 | 19 | 0.94 | 8 | 0.39 | 27 | 1.33 | 0.88 to 1.94 | |
Tajikistan | Skarzyński et al. 2016 | 143 | NA | NA | NA | NA | 34 | 23.70 | 17.06 to 31.61 |
Jordan | Alaqrabawi et al.74 2016 | 1649 | 54 | 3.27 | 36 | 2.18 | 90 | 5.45 | 4.41 to 6.61 |
Iraq | Al-Obeidy et al.75 2019 | 425 | 28 | 6.59 | 2 | 0.47 | 30 | 7.06 | 4.81 to 9.92 |
China | Lu et al.44 2011 | 21 547 | 285 | 1.32 | 16 | 0.07 | 301 | 1.39 | 1.24 to 1.56 |
Chen et al. 38 2012 | 28 546 | 344 | 1.21 | 22 | 0.08 | 366 | 1.29 | 1.15 to 1.42 |
CDHL, conductive hearing loss; HL, hearing loss; LB, lower bound; NA, not mentioned; NHL, neural hearing loss; SNHL, sensorineural hearing loss; UB, upper bound.